Geneva Capital Management LLC Has $14.21 Million Stock Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

Geneva Capital Management LLC lessened its position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 42.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 874,485 shares of the medical equipment provider’s stock after selling 650,906 shares during the quarter. Geneva Capital Management LLC’s holdings in BioLife Solutions were worth $14,210,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC increased its position in shares of BioLife Solutions by 167.2% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,630 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 1,020 shares during the period. GAMMA Investing LLC acquired a new stake in BioLife Solutions during the 4th quarter worth about $41,000. Allspring Global Investments Holdings LLC raised its position in shares of BioLife Solutions by 88.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 11,346 shares of the medical equipment provider’s stock worth $157,000 after acquiring an additional 5,324 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of BioLife Solutions by 8.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,622 shares of the medical equipment provider’s stock valued at $216,000 after purchasing an additional 1,164 shares during the period. Finally, Dark Forest Capital Management LP bought a new stake in shares of BioLife Solutions during the 3rd quarter valued at about $223,000. Institutional investors own 93.24% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group began coverage on BioLife Solutions in a report on Thursday, April 4th. They issued a “buy” rating and a $22.00 target price for the company. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $23.40.

BioLife Solutions Stock Up 11.2 %

Shares of NASDAQ BLFS traded up $2.01 during trading on Friday, hitting $20.02. 534,617 shares of the company traded hands, compared to its average volume of 412,129. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.83 and a current ratio of 2.86. The business’s fifty day moving average is $17.45 and its 200 day moving average is $15.83. The firm has a market capitalization of $906.91 million, a price-to-earnings ratio of -13.28 and a beta of 1.69. BioLife Solutions, Inc. has a fifty-two week low of $8.92 and a fifty-two week high of $24.50.

BioLife Solutions (NASDAQ:BLFS) last issued its earnings results on Thursday, May 9th. The medical equipment provider reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.06. BioLife Solutions had a negative return on equity of 13.36% and a negative net margin of 46.37%. The company had revenue of $31.73 million for the quarter, compared to analysts’ expectations of $29.30 million. During the same period last year, the business earned ($0.27) EPS. Equities research analysts predict that BioLife Solutions, Inc. will post -0.6 earnings per share for the current fiscal year.

Insider Buying and Selling at BioLife Solutions

In related news, CEO Greef Roderick De sold 7,249 shares of BioLife Solutions stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $16.60, for a total transaction of $120,333.40. Following the sale, the chief executive officer now directly owns 461,854 shares in the company, valued at $7,666,776.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Greef Roderick De sold 7,249 shares of the company’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $16.60, for a total transaction of $120,333.40. Following the sale, the chief executive officer now directly owns 461,854 shares in the company, valued at $7,666,776.40. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CMO Todd Berard sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $15.67, for a total transaction of $156,700.00. Following the completion of the transaction, the chief marketing officer now owns 129,644 shares of the company’s stock, valued at $2,031,521.48. The disclosure for this sale can be found here. In the last three months, insiders have sold 33,996 shares of company stock worth $562,145. Corporate insiders own 2.70% of the company’s stock.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.